Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Anne M M OonkEsther H Lips

Abstract

We have previously reported an array comparative genomic hybridization profile that identifies triple-negative breast cancers (TNBC), with BRCA1 dysfunction and a high sensitivity to intensified dose bifunctional alkylating agents. To determine the effect of conventional-dose chemotherapy in patients with this so-called BRCA1-like profile, clinical characteristics and survival were studied in a large group of TNBC patients. DNA was isolated and BRCA1-like status was assessed in 101 patients with early-stage TNBC receiving adjuvant cyclophosphamide-based chemotherapy. Clinical characteristics and survival were compared between BRCA1-like and non-BRCA1-like groups. Results Sixty-six tumors (65%) had a BRCA1-like profile. Patients with BRCA1-like tumors tended to be younger and had more often node-negative disease (P = 0.06 and P = 0.03, respectively). Five-year recurrence-free survival was 80% for the BRCA1-like group and 75% for the non-BRCA1-like group (P = 0.35). T stage was the only variable significantly associated with survival. BRCA1-like tumors share clinical features, like young age at diagnosis and similar nodal status, with breast cancers in BRCA1 mutation carriers. Their prognosis is similar to that of non-BRCA1-like ...Continue Reading

References

May 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·Robert TibshiraniGilbert Chu
Aug 22, 2003·Annals of Tropical Medicine and Parasitology·S Biswas
Jul 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Sven RottenbergPiet Borst
Apr 17, 2008·Cancer Research·Elizabeth M SwisherToshiyasu Taniguchi
Aug 16, 2008·Breast Cancer Research and Treatment·Simon A JoossePetra M Nederlof
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jul 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mieke KriegeJan G M Klijn
Aug 12, 2009·Breast Cancer Research and Treatment·Jorma J de RondeSjoerd Rodenhuis
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Panagiotis A KonstantinopoulosStephen A Cannistra
Oct 13, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E H LipsS Rodenhuis
Dec 8, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A VolleberghS C Linn

❮ Previous
Next ❯

Citations

Jul 19, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jie RenMinjie Wei
Dec 12, 2012·Current Opinion in Obstetrics & Gynecology·Mythili Shastry, Denise A Yardley
Nov 8, 2014·Molecules and Cells·Hui WangJingting Jiang
Dec 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C WangY Xie
Jul 12, 2019·Expert Review of Molecular Diagnostics·Zhen WangXiaofeng Dai
Jul 25, 2013·The Oncologist·Pavani Chalasani, Robert Livingston
Nov 28, 2015·Breast Cancer Research and Treatment·M T BranhamM Roqué
Dec 5, 2020·Scientific Reports·Lei LiuSeigo Nakamura
Jan 22, 2021·The Cancer Journal·Rachel M Layman, Banu Arun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.